![]() |
NORTHERA™ (droxidopa) Phase III, for Neurogenic Orthostatic Hypotension
Chelsea Therapeutics Announces Interim Results and Plans to Modify Study 306 to Focus on Reduction in Falls Associated With Neurogenic Orthostatic Hypotension
See NT PD Clinical Trials....click above to go to there |
All times are GMT -5. The time now is 01:21 PM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.